Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059416 | 1.00 | TLR7 (0.32) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL5508561 | 0.81 | ADORA2A (0.33) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2059203 | 0.78 | TLR7 (0.52) | TLR7ADORA2A | |
| SCHEMBL2059201 | 0.78 | TLR7 (0.52) | TLR7ADORA2A | |
| SCHEMBL8113615 | 0.76 | TLR7 (0.40) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL842243 | 0.76 | PDE4D (0.37) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| Hydrochloric Acid SCHEMBL2059226 | 0.73 | TLR7 (0.41) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL8114799 | 0.72 | TLR7 (0.42) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL5119127 | 0.72 | TLR7 (0.40) | TLR7ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2059175 | 0.72 | TLR7 (0.39) | TLR7ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968563-B2 | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968563-B2 | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968563-B2 | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100069427-A9 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069427-A9 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069427-A9 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090062328-A1 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062328-A1 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062328-A1 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069427-A9 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | IFNG, IL4, IRF3 | TLR7 76/4885ADORA3 1324/4885ADORA2A 1617/4885 |
| US-20090062328-A1 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | IFNG, IL4, IRF3 | TLR7 76/4885ADORA3 1324/4885ADORA2A 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.